PROTHENA CORPORATION PUBLIC LIMITED COMPANY

PRTA ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-244.1M $-122.3M $-147.0M $-116.9M $67.0M $-111.1M $-77.7M $-155.6M
Depreciation & Amortization $895.0K $893.0K $928.0K $744.0K $1.1M $1.5M $1.6M $3.2M
Depreciation $900.0K $900.0K $900.0K $700.0K $1.1M $1.5M $1.6M $3.2M
Amortization
Stock-Based Compensation $37.6M $46.0M $40.9M $31.3M $24.7M $22.0M $23.6M $27.0M
Net Cash from Operating Activities $-163.6M $-150.1M $-133.9M $-108.8M $92.6M $-80.4M $-53.0M $-28.3M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $-138.0K $-298.0K $-2.8M $-464.0K $-575.0K $-196.0K $-547.0K $-1.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-139.0K $1.6M $45.1M $241.5M $190.3M $215.0K $228.0K $40.0M
Net Change in Cash
Free Cash Flow
← Newer Page 1 of 2 Older →